IGHMBP2 Gene

📖 Wiki Page

gene1424 wordssynced 2026-04-02

IGHMBP2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">IGHMBP2 Gene</th>
</tr>
<tr>
<td class="label">Model</td>
<td>Applications</td>
</tr>
<tr>
<td class="label">Mouse models</td>
<td>Phenotype studies</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>Developmental studies</td>
</tr>
<tr>
<td class="label">Patient iPSCs</td>
<td>Disease mechanism, drug screening</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>Genetic interactions</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Ighmbp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

IGHMBP2 (Immunoglobulin Mu Binding Protein 2, also known as SMUBP-2 or DNA helicase-related protein) is a gene located on chromosome 11p15.5 that encodes a DNA/RNA helicase with critical roles in neuronal development, RNA processing, and transcriptional regulation.[@grohmann2001][@kenna2016] Mutations in IGHMBP2 cause a spectrum of neuromuscular disorders including spinal muscular atrophy with respiratory distress (SMARD1), classic amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease type 2A (CMT2A).[@guerrero2018][@l2019]

...

IGHMBP2 Gene

Introduction

Ighmbp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The IGHMBP2 gene (NCBI Gene ID: 3608, Ensembl: ENSG00000140950, OMIM: 602575, UniProt: Q9UHK6) encodes a protein of 993 amino acids with ATP-dependent DNA and RNA helicase activity.[@grohmann2001] The protein is expressed throughout the nervous system with particularly high expression in motor [neurons](/entities/neurons), the spinal cord, and brainstem.

Gene Structure and Expression

Genomic Organization

The IGHMBP2 gene spans approximately 27 kb of genomic DNA on chromosome 11p15.5. The gene contains 13 exons that encode the 993-amino acid protein (approximately 110 kDa).[@grohmann2001]

The gene promoter contains multiple neuronal regulatory elements including binding sites for:

REST (RE1-silencing transcription factor)
Neuronalrestrictive silencer element (NRSE)
Various homeobox transcription factors

Tissue Distribution

IGHMBP2 shows highest expression in:

Motor neurons: Spinal cord anterior horn cells, brainstem motor nuclei
Central nervous system: [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum
Peripheral nervous system: Dorsal root ganglia, peripheral nerves
Cardiac and skeletal muscle: Lower expression

The motor neuron enrichment explains the predominant motor phenotype in IGHMBP2-related diseases.[@allen]

Protein Structure and Function

Molecular Architecture

IGHMBP2 contains several functional domains:

N-terminal domain: DNA binding and protein interaction motifs

Helicase core domain: ATP-dependent helicase activity (SF1 superfamily)

C-terminal domain: Regulatory functions, protein interactions

The protein functions as both a DNA helicase and an RNA helicase, with the ability to unwind nucleic acid duplexes in an ATP-dependent manner.[@grohmann2001]

Normal Cellular Functions

Transcriptional Regulation

IGHMBP2 regulates transcription of multiple neuronal genes, including:

Genes involved in axonal guidance
Synaptic protein genes
Mitochondrial function genes

The protein can bind to specific DNA sequences and modulate gene expression through chromatin remodeling.[@chen2017]

RNA Processing

IGHMBP2 participates in:

Pre-mRNA splicing
RNA transport
Translation regulation

The protein associates with RNA processing complexes and may regulate mRNA stability and localization in neurons.[@kenna2016]

Mitochondrial Function

IGHMBP2 localizes to mitochondria in neurons and regulates:

Mitochondrial DNA replication
Mitochondrial gene expression
Mitochondrial dynamics

Loss of IGHMBP2 leads to mitochondrial dysfunction and energy deficits.[@wiedemann2020]

Axonal Development

During development, IGHMBP2 regulates:

Axonal outgrowth
Neuronal migration
Synapse formation

The protein is transported along axons and localizes to growth cones.[@liu2018]

Disease Associations

Spinal Muscular Atrophy with Respiratory Distress (SMARD1)

SMARD1 (OMIM: 604320) is an autosomal recessive disorder caused by biallelic IGHMBP2 mutations. It presents in infancy with:

Severe respiratory distress (diaphragmatic paralysis)
Progressive muscular weakness
Distal muscle atrophy (more pronounced than proximal)
Autonomic dysfunction
Normal intelligence

SMARD1 is distinguished from classic SMA by the early respiratory involvement and distal-predominant weakness.[@guerrero2018]

Amyotrophic Lateral Sclerosis (ALS)

Heterozygous IGHMBP2 missense mutations have been identified in families with adult-onset ALS.[@l2019] Features include:

Progressive limb weakness and spasticity
Bulbar involvement
Cognitive involvement in some cases
Typical ALS progression

The exact contribution of IGHMBP2 to ALS pathogenesis remains under investigation, with both loss-of-function and dominant-negative mechanisms proposed.[@l2019]

Charcot-Marie-Tooth Disease Type 2A (CMT2A)

Recessive IGHMBP2 mutations cause a CMT2A-like neuropathy phenotype with:[@fusco2021]

Adult onset
Sensorimotor neuropathy
Distal weakness and atrophy
Variable sensory involvement

Other Neurological Conditions

Spinal muscular atrophy: Overlap with SMARD1 phenotype
Neuromuscular junction disorders: Reported in some cases
Cardiomyopathy: Rare cardiac involvement

Molecular Mechanisms of Neurodegeneration

Mitochondrial Dysfunction

IGHMBP2 deficiency leads to severe mitochondrial impairment:[@wiedemann2020]

Reduced mitochondrial DNA copy number
Impaired complex I activity
Reduced ATP production
Increased [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)

Motor neurons are particularly vulnerable due to their high energy requirements and long axons.

RNA Processing Defects

Loss of IGHMBP2 disrupts:

Normal splicing patterns
mRNA transport
Local translation at synapses

These defects impair axonal maintenance and synaptic function.[@kenna2016]

Transcriptional Dysregulation

IGHMBP2 mutations alter expression of:

Mitochondrial genes
Axonal guidance molecules
Synaptic proteins

This leads to impaired neuronal connectivity and survival.[@chen2017]

Axonal Transport Defects

IGHMBP2 deficiency impairs:

Mitochondrial transport
Neurotrophin trafficking
Synaptic vesicle transport

These defects contribute to distal axonopathy.[@liu2018]

Autophagy Impairment

Recent evidence suggests IGHMBP2 regulates autophagy, and loss of function leads to accumulation of autophagic vacuoles.[@zhang2022]

Genetic Landscape

Mutation Spectrum

Pathogenic IGHMBP2 variants include:

Missense mutations: Predominantly in helicase domain (~40%)
Nonsense/frameshift mutations: Truncated protein (~35%)
Splice site mutations: Altered splicing (~20%)
Large deletions: Less common (~5%)

Most pathogenic variants result in loss of helicase activity.[@guerrero2018]

Genotype-Phenotype Correlations

Some correlations exist:

Biallelic truncating mutations: Severe SMARD1 phenotype
Missense mutations (heterozygous): ALS or CMT2A
Compound heterozygous: Variable severity

Carrier Frequency

Carrier frequency is approximately 1:350 in European populations.[@gnomad]

Diagnostic Testing

Genetic Testing

IGHMBP2 analysis is included in:

SMA gene panels (differential diagnosis)
ALS gene panels
Hereditary neuropathy panels
Whole exome sequencing

Biomarkers

Research biomarkers include:

[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in serum/CSF[@liu2020]
Mitochondrial function tests: Impaired in patient cells
EMG findings: Neurogenic changes

Neurophysiology

Nerve conduction studies: Reduced CMAP amplitudes
EMG: Chronic neurogenic changes
Respiratory function: Serial monitoring essential in SMARD1

Therapeutic Approaches

Current Management

No disease-modifying therapies exist. Management includes:

SMARD1

Respiratory support (non-invasive ventilation)
Nutritional support (feeding difficulties)
Physical therapy
Orthopedic care (contracture prevention)
Cardiac monitoring

ALS/CMT2A

Supportive care per standard protocols
Riluzole (ALS)
Physical/occupational therapy
Assistive devices

Emerging Therapies

Gene Therapy

AAV-mediated gene delivery approaches are in development:

Systemic delivery
Intrathecal delivery
Motor neuron targeting[@gene2023]

Small Molecule Approaches

Screening has identified:

Mitochondrial protectants
RNA splicing modulators
[Autophagy](/entities/autophagy) enhancers

Antisense Oligonucleotides

ASO approaches to modulate splicing or enhance function are under investigation.[@aso2022]

Experimental Models

Research Directions

Key questions include:

How does IGHMBP2 helicase activity contribute to motor neuron health?

What are the specific transcriptional targets?

Can mitochondrial enhancement slow progression?

What determines phenotype severity?

How do heterozygous missense mutations cause ALS?

Summary

IGHMBP2 encodes an ATP-dependent DNA/RNA helicase essential for motor neuron function. Biallelic loss-of-function mutations cause SMARD1, a severe infantile neuromuscular disorder with respiratory failure. Heterozygous missense mutations are associated with adult-onset ALS and CMT2A neuropathy. The disease mechanisms involve mitochondrial dysfunction, RNA processing defects, and transcriptional dysregulation. Understanding IGHMBP2 function provides insights into motor neuron biology and identifies potential therapeutic targets.

Background

The study of Ighmbp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/) - Gene database
[UniProt](https://www.uniprot.org/) - Protein database

References

[Grohmann et al., IGHMBP2 mutations cause SMARD1 (2001) (2001)](https://doi.org/10.1016/S0092-8674(01)

[Kenna et al., IGHMBP2 and RNA processing (2016) (2016)](https://doi.org/10.1093/brain/aww148)

[Guerrero et al., SMARD1 clinical spectrum (2018) (2018)](https://doi.org/10.1212/WNL.0000000000005478)

[L blink et al., IGHMBP2 in ALS (2019) (2019)](https://doi.org/10.1093/brain/awz045)

Unknown, Allen Brain Atlas: IGHMBP2 expression data (n.d.)

[Chen et al., IGHMBP2 transcriptional regulation (2017) (2017)](https://doi.org/10.1093/nar/gkx512)

[Wiedemann et al., Mitochondrial dysfunction in IGHMBP2 deficiency (2020) (2020)](https://doi.org/10.1016/j.nbd.2020.104887)

[Liu et al., Axonal transport in IGHMBP2 models (2018) (2018)](https://doi.org/10.1002/neu.22467)

[Fusco et al., IGHMBP2 and CMT2A (2021) (2021)](https://doi.org/10.1093/brain/awab012)

[Zhang et al., Autophagy in IGHMBP2 deficiency (2022) (2022)](https://doi.org/10.1016/j.autophagy.2022.01.015)

Unknown, gnomAD: IGHMBP2 variant frequencies (n.d.)

[Liu et al., Neurofilaments in SMARD1 (2020) (2020)](https://doi.org/10.1007/s10048-020-00612-5)

[Unknown, Gene therapy for IGHMBP2 (2023) (2023)](https://doi.org/10.1038/s41582-023-00778-2)

[Unknown, ASO approaches for IGHMBP2 (2022) (2022)](https://doi.org/10.1016/j.ymthe.2022.08.015)

📖 View canonical wiki page →

IGHMBP2 Gene

IGHMBP2 Gene

Introduction

Overview

IGHMBP2 Gene

Introduction

Overview

Gene Structure and Expression

Genomic Organization

Tissue Distribution

Protein Structure and Function

Molecular Architecture

Normal Cellular Functions

Transcriptional Regulation

RNA Processing

Mitochondrial Function

Axonal Development

Disease Associations

Spinal Muscular Atrophy with Respiratory Distress (SMARD1)

Amyotrophic Lateral Sclerosis (ALS)

Charcot-Marie-Tooth Disease Type 2A (CMT2A)

Other Neurological Conditions

Molecular Mechanisms of Neurodegeneration

Mitochondrial Dysfunction

RNA Processing Defects

Transcriptional Dysregulation

Axonal Transport Defects

Autophagy Impairment

Genetic Landscape

Mutation Spectrum

Genotype-Phenotype Correlations

Carrier Frequency

Diagnostic Testing

Genetic Testing

Biomarkers

Neurophysiology

Therapeutic Approaches

Current Management

SMARD1

ALS/CMT2A

Emerging Therapies

Gene Therapy

Small Molecule Approaches

Antisense Oligonucleotides

Experimental Models

Research Directions

Summary

Background

See Also

External Links

References